Otoro

Harungana madagascariensis stembark and leaf extracts contain high concentrations of phenolics (up to 132.24 mg GAE/g), flavonoids (up to 259.05 mg QE/g), and anthranoid compounds—ferruginin A, euxanthone, harunmadagascarin D, and kenganthranol C—that disrupt bacterial cytoplasmic membrane integrity, inhibit catalase activity, and scavenge free radicals via ferric-reducing antioxidant mechanisms. In vitro studies demonstrate that leaf extract at sub-MIC concentrations (MIC/8) reduces the minimum inhibitory concentration of doxycycline against Pseudomonas aeruginosa by at least 16-fold, and acute toxicity data in mice show a relatively wide safety margin with intraperitoneal LD50 values of 1,000–1,414 mg/kg.

Origin & History

Harungana madagascariensis is a fast-growing shrub or small tree indigenous to tropical Africa, Madagascar, and parts of the Arabian Peninsula, thriving in secondary forests, forest margins, and disturbed habitats at altitudes up to 2,400 meters. It is widely distributed across sub-Saharan Africa, including Nigeria, Cameroon, Ghana, Uganda, and the Democratic Republic of Congo, where it colonizes clearings and roadsides in humid and sub-humid zones. The plant is not commercially cultivated but is harvested wild by local communities who utilize its stembark, leaves, and fruits for medicinal preparations.

Historical & Cultural Context

Harungana madagascariensis holds a significant place in the ethnomedicinal traditions of numerous African peoples, where it is variously known as Otoro in Nigeria, dragon's blood tree, and harungana across the broader continent, reflecting its wide geographic footprint and cultural relevance. Traditional healers in Nigeria, Ghana, Cameroon, and the Democratic Republic of Congo have long prepared stembark decoctions and leaf poultices for the treatment of parasitic infections including trypanosomiasis (sleeping sickness), hemorrhoids, skin diseases, gonorrhea, and dysentery, typically using aqueous boiling or cold maceration techniques passed through oral tradition. The plant's reddish sap, which exudes from cut surfaces and resembles blood or dragon's blood resin, has contributed to its symbolic and ritual significance in some communities, where it is also used as a wound-healing agent and to treat jaundice. Its inclusion in formal ethnobotanical surveys across multiple African countries underscores its sustained relevance in primary healthcare systems where access to pharmaceutical medicine remains limited.

Health Benefits

- **Antioxidant Protection**: Stembark methanolic extracts contain exceptionally high phenolics (132.24 ± 0.61 mg GAE/g) and flavonoids (259.05 ± 2.85 mg QE/g) that exhibit potent ferric-reducing antioxidant power in vitro, suggesting utility in mitigating oxidative stress-related cellular damage.
- **Antibacterial Activity**: Leaf extracts demonstrate antibacterial effects against Pseudomonas aeruginosa by disrupting cytoplasmic membrane integrity and inhibiting catalase, with MIC values ranging from 16 to 2,048 µg/mL; specific anthranoid compounds—ferruginin A and euxanthone—are primary contributors to this activity.
- **Antibiotic Potentiation**: At sub-inhibitory concentrations (MIC/8), leaf extracts enhance the efficacy of conventional antibiotics such as doxycycline by at least 16-fold reduction in MIC, suggesting a clinically relevant role in combating antibiotic-resistant infections.
- **Antiparasitic Use (Ethnomedicinal)**: Traditional practitioners across sub-Saharan Africa employ stembark preparations to treat trypanosomiasis, with bioactive alkaloids and anthraquinones hypothesized to interfere with parasite metabolism, though direct mechanistic evidence remains preclinical.
- **Hemorrhoid Relief (Ethnomedicinal)**: Stembark and leaf preparations are used traditionally to treat piles (hemorrhoids), plausibly attributed to tannin-mediated astringent effects and anti-inflammatory flavonoid activity on inflamed rectal mucosa.
- **Anti-inflammatory Potential**: Terpenes and flavonoids identified in stembark and leaf fractions are associated with inhibition of pro-inflammatory enzymatic pathways in related Hypericaceae species, suggesting Harungana madagascariensis may share comparable anti-inflammatory properties pending direct investigation.
- **Nutritive Mineral Supplementation**: Stembark contains meaningful concentrations of manganese (29.44 ± 0.03 mg/100g DW), magnesium (25.99 ± 0.04 mg/100g DW), and B vitamins including B1 (23.14 ± 0.03 mg/100g DW) and B2 (18.22 ± 0.03 mg/100g DW), which may contribute to cofactor availability in enzymatic and metabolic processes.

How It Works

Leaf extracts of Harungana madagascariensis exert antibacterial effects primarily by disrupting cytoplasmic membrane integrity in Gram-negative organisms such as Pseudomonas aeruginosa, leading to ion leakage, loss of membrane potential, and cell death; simultaneously, catalase enzyme inhibition within bacterial cells increases intracellular reactive oxygen species accumulation, amplifying oxidative damage to bacterial DNA and proteins. Anthranoid compounds—specifically ferruginin A, euxanthone, harunmadagascarin D, and kenganthranol C—are the principal bioactive agents responsible for targeting bacterial membrane and enzymatic pathways, with their planar aromatic ring systems facilitating intercalation into lipid bilayers and disruption of electron transport. The high phenolic and flavonoid content (up to 259 mg QE/g in stembark) contributes to antioxidant mechanisms via direct free radical scavenging, metal chelation through hydroxyl and carbonyl functional groups, and ferric ion reduction, collectively attenuating oxidative stress at the cellular level. Tannins in the stembark exert additional astringent effects by forming complexes with proteins on mucosal surfaces, which may underlie the traditional use in treating hemorrhoids by promoting vasoconstriction and local tissue contraction.

Scientific Research

The available evidence for Harungana madagascariensis is exclusively preclinical, consisting of in vitro phytochemical characterization, antioxidant assays, antibacterial susceptibility testing, and acute toxicity studies in murine models; no randomized controlled trials, observational cohort studies, or any form of human clinical investigation have been published in accessible peer-reviewed literature. Antibacterial studies using leaf dichloromethane and methanolic extracts report MIC values of 16–2,048 µg/mL against Pseudomonas aeruginosa and demonstrate ≥16-fold potentiation of doxycycline efficacy at sub-MIC concentrations, providing mechanistic insight but no translational clinical validation. Acute toxicity profiling in mice establishes intraperitoneal LD50 values of 1,000 ± 8.0 mg/kg for dichloromethane stembark extract and 1,414 ± 8.2 mg/kg for methanolic stembark extract, indicating low-to-moderate acute toxicity but offering no chronic safety data. The evidence base is currently insufficient to draw conclusions about therapeutic efficacy in humans, and the gap between in vitro bioactivity and clinically meaningful outcomes remains unbridged.

Clinical Summary

No human clinical trials evaluating Harungana madagascariensis for any indication—including its primary traditional uses of treating hemorrhoids and trypanosomiasis—have been identified in available scientific databases. All quantitative outcome data derive from in vitro experiments and rodent acute toxicity studies, limiting any extrapolation of effect size, therapeutic dose, or safety profile to human populations. The most quantitatively robust findings involve the 16-fold or greater reduction in doxycycline MIC against Pseudomonas aeruginosa and antioxidant activity indices, both of which represent surrogate endpoints with unknown clinical relevance. Confidence in therapeutic outcomes remains very low due to the complete absence of human pharmacokinetic, pharmacodynamic, or efficacy data.

Nutritional Profile

Stembark of Harungana madagascariensis contains modest but measurable quantities of essential minerals, with manganese at 29.44 ± 0.03 mg/100g DW and magnesium at 25.99 ± 0.04 mg/100g DW being the most abundant, followed by iron at 2.50 ± 0.02 mg/100g DW; B-vitamin content is notable, with thiamine (B1) at 23.14 ± 0.03 mg/100g DW and riboflavin (B2) at 18.22 ± 0.03 mg/100g DW, alongside vitamin A at 4.18 ± 0.02 mg/100g DW and vitamin C at 0.26 ± 0.01 mg/100g DW. Phytochemical constituents are dominated by phenolics (132.24 mg GAE/g in stembark methanolic extract), flavonoids (259.05 mg QE/g in stembark methanolic extract), tannins (0.97 ± 0.02 mg/100g DW), alkaloids (1.14 ± 0.08 mg/100g), and saponins (0.48 ± 0.09 mg/100g), with anthraquinones, cardiac glycosides, and terpenes also confirmed by qualitative screening. Antinutrient levels are reassuringly low: phytic acid at 0.01 ± 0.01 mg/100g DW, soluble oxalate at 3.03 ± 0.02 mg/100g DW (well below the 5 mg/100g threshold of concern), and hydrocyanide at 0.75 mg/100g DW (far below the lethal threshold of 35 mg/100g), indicating that antinutrient interference with mineral bioavailability is minimal. No macronutrient (protein, fat, carbohydrate) composition data are available from the published sources, and bioavailability studies for any micronutrient or phytochemical in humans have not been conducted.

Preparation & Dosage

- **Traditional Stembark Decoction**: Stembark is boiled in water and consumed orally for hemorrhoids and trypanosomiasis in West and Central African traditional medicine; no standardized volume or frequency has been clinically established.
- **Methanolic Extract (Research Grade)**: Used in laboratory studies at concentrations of 2 mg/mL for phenolic quantification and 16–2,048 µg/mL for antibacterial minimum inhibitory concentration determination; not applicable as a consumer supplement dose.
- **Dichloromethane Extract (Research Grade)**: Applied in antibacterial and toxicity studies; LD50 established at 1,000 mg/kg i.p. in mice, suggesting a safety buffer for oral exposure but no oral bioavailability data confirmed.
- **Leaf Extract**: Used in antibacterial studies at sub-MIC concentrations (MIC/8) to assess antibiotic potentiation; no leaf extract supplement form is commercially available.
- **Standardization**: No commercial standardization to specific marker compounds (e.g., euxanthone, ferruginin A, or phenolic content) exists; all concentration data derive from academic phytochemical studies.
- **Dosage Note**: No safe or effective human dosage has been established; use of any preparation should be under ethnomedicine guidance until clinical data are available.

Synergy & Pairings

Harungana madagascariensis leaf extracts demonstrate mechanistic synergy with doxycycline against Pseudomonas aeruginosa, where sub-inhibitory concentrations (MIC/8) of the extract reduce the antibiotic's MIC by at least 16-fold, likely through complementary mechanisms of membrane disruption by anthranoids and antibiotic target engagement, reducing the antibiotic dose required for bacteriostasis. In traditional African polyherbalism, Harungana madagascariensis is often combined with other tannin-rich astringent plants (such as Terminalia species) for hemorrhoid management, where additive mucosal protein-binding and vasoconstriction effects may be expected based on shared tannin chemistry. Theoretically, co-administration with vitamin C or other reducing agents could stabilize its labile phenolic antioxidants and enhance radical scavenging capacity, but no experimental evidence for this combination exists in the published literature for this species.

Safety & Interactions

Acute toxicity studies in mice indicate a relatively moderate safety profile, with intraperitoneal LD50 values of 1,000 ± 8.0 mg/kg for dichloromethane stembark extract and 1,414 ± 8.2 mg/kg for methanolic stembark extract; however, intraperitoneal LD50 does not directly translate to oral toxicity thresholds, and no chronic toxicity, subacute toxicity, genotoxicity, or reproductive toxicity studies have been reported. The presence of cardiac glycosides in phytochemical screening warrants caution, as these compounds can potentiate or antagonize cardiac medications including digoxin, antiarrhythmics, and diuretics; concurrent use with cardioactive drugs should be avoided until interaction studies are conducted. No data are available regarding drug interactions with antiparasitic agents (e.g., melarsoprol, suramin, pentamidine), anticoagulants, or hepatically metabolized pharmaceuticals, and the cytochrome P450 interaction profile of key anthranoid and alkaloid constituents is entirely unstudied. Use during pregnancy and lactation is not recommended given the complete absence of safety data in these populations, the known uterotonic potential of alkaloid-containing African botanicals, and the presence of anthraquinones, which have cathartic and potentially abortifacient properties in related species.